Experimental reversal of P-glycoprotein-mediated multidrug resistance by pharmacological chemosensitisers

European Journal of Cancer

Volumn 32, Issue 6, 1996, Pages 991-1001

  Ford, J M ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 BIS(ALLYLAMINO) 6 [4 [[2,2 BIS(4 FLUOROPHENYL)ETHYL]AMINO]PIPERIDINO] 1,3,5 TRIAZINE; AMIODARONE; ANTINEOPLASTIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; CALMODULIN INHIBITOR; CARRIER PROTEIN; CYCLOPEPTIDE; CYCLOSPORIN A; CYTOTOXIC AGENT; DIPYRIDAMOLE; GALLOPAMIL; GENE PRODUCT; GLYCOPROTEIN P; MEGESTROL ACETATE; METHADONE; PROGESTERONE; PROTEIN KINASE C INHIBITOR; QUINIDINE; RAPAMYCIN; RESERPINE; SDZ 280446; STEROID; TACROLIMUS; TAMOXIFEN; TERFENADINE; TOREMIFENE; UNINDEXED DRUG; VALSPODAR; VERAPAMIL; VINCA ALKALOID;

CANCER CELL DESTRUCTION; CANCER RESISTANCE; DRUG TRANSPORT; HUMAN; HUMAN CELL; LIGAND BINDING; MULTIDRUG RESISTANCE; PHENOTYPE; PRIORITY JOURNAL; REVIEW;

ANTINEOPLASTIC AGENTS, HORMONAL; CALCIUM CHANNEL BLOCKERS; CALMODULIN; DIPYRIDAMOLE; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; P-GLYCOPROTEIN; PEPTIDES, CYCLIC; PROTEIN PROCESSING, POST-TRANSLATIONAL; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0029939665     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/0959-8049(96)00047-0     Document Type: Article

References (161)

1. Ford JM, Hait WN. Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 1990, 42, 156-199.
2. Ford JM. Modulators of multidrug resistance: preclinical studies. Hematol Oncol Clin North Am 1995, 9, 337-355.
3. Biedler JL, Riehm H. Cellular resistance to actinomycin D in Chinese hamster cells in vitro: cross-resistance, radioautographic and cytogenetic studies. Cancer Res 1970, 30, 1174-1184.
4. Dano K. Active outward transport of daunomycin in resistant Ehrlich ascites tumour cells. Biochim Biophys Acta 1973, 323, 466-483.
5. Yeh GC, Lopaczynska J, Poore CM, Phang JM. A new functional role for P-glycoprotein: efflux pump for benzo(a)pyrene in human breast cancer MCF-7 cells. Cancer Res 1992, 52, 6692-6695.
6. Ueda K, Okamura N, Hirai M, et al. Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone. J Biol Chem 1992, 267.
7. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 1976, 455, 152-162.
8. Skovsgaard T. Mechanisms of resistance to daunorubicin in Ehrlich ascites tumour cells. Cancer Res 1978, 38, 1785-1791.
9. Kartner N, Riordan JR, Ling V. Cell surface P-glycoprotein is associated with multidrug resistance in mammalian cell lines. Science 1983, 221, 1285-1288.
10. Gerlach JH, Kartner N, Bell DR, Ling V. Multidrug resistance. Cancer Surv 1986, 5, 25-46.
11. Gros P, Neriah BY, Croop JM, Housman DE. Isolation and expression of a complementary DNA that confers multidrug resistance. Nature 1986, 323, 728-731.
12. Ueda K, Cardarelli C, Gottesman MM, Pastan I. Expression of a full-length cDNA for the human mdr1 gene confers resistance to colchicine, doxorubicin, and vinblastine. Proc Natl Acad Sci USA 1987, 84, 3004-3008.
13. 3H] vinblastine from Chinese hamster ovary cells transfected with a full-length complementary DNA clone for the mdr1 gene. Cancer Res 1989, 49, 3867-3871.
14. Bibi E, Gros P, Kaback HR. Functional expression of mouse mdrl in Escherichia coli. Proc Natl Acad Sci USA 1993, 90, 9209-9213.
15. Ruetz S, Raymond M, Gros P. Functional expression of p-glycoprotein encoded by the mouse mdr3 gene in yeast cells. Proc Natl Acad Sci USA 1993, 90, 11588-11592.
16. Raymond M, Ruetz S, Thomas DY, Gros P. Functional expression of P-glycoprotein in Saccharomyces cerevisiae confers cellular resistance to the immunosuppressive and antifungal agent FK520. Mol Cell Biol 1994, 14, 277-286.
17. Ruetz S, Gros P. Functional expression of P-glycoproteins in secretory vesicles. J Biol Chem 1994, 269, 12277-12284.
18. Gros P, Croop J, Housman D. Mammalian multidrug resistance gene: complete cDNA sequence indicates strong homology to bacterial transport proteins. Cell 1986, 47, 371-380.
19. Chen CJ, Chin E, Ueda K, et al. Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug resistant human cells. Cell 1986, 47, 381-389.
20. Gros P, Shustik C. Multidrug resistance: a novel class of membrane-associated transport proteins is identified. Cancer Invest 1991, 9, 563-569.
21. Higgins CF. The ABC of channel regulation. Cell 1995, 82, 693-696.
22. Sharom FJ, Yu X, Doige CA. Functional reconstitution of drug transport and ATPase activity in proteoliposomes containing partially purified P-glycoprotein. J Biol Chem 1993, 268, 24197-24202.
23. Shapiro AB, Ling V. ATPase activity of purified and reconstituted P-glycoprotein from Chinese hamster ovary cells. J Biol Chem 1994, 269, 3745-3754.
24. Shapiro AB, Ling V. Reconstitution of drug transport by purified P-glycoprotein. J Biol Chem 1995, 27, 16167-16175.
25. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 1993, 62, 385-427.
26. Higgins CF. To flip or not to flip? Curr Biol 1994, 4, 259-260.
27. Cornwell MM, Pastan I, Gottesman MM. Certain calcium channel blockers bind specifically to multidrug resistant human KB carcinoma membrane vesicles and inhibit drug binding to P-glycoprotein. J Biol Chem 1987, 262, 2166-2170.
28. Loo TW, Clarke DM. Functional consequences of glycine mutations in the predicted cytoplasmic loops of P-glycoprotein. J Biol Chem 1994, 269, 7243-7248.
29. Loo TW, Clarke DM. Functional consequences of phenylalanine mutations in the predicted transmembrane domains of P-glycoprotein. J Biol Chem 1994, 268, 19965-19972.
30. Morris DI, Greenberger LM, Bruggemann EP, et al. Localization of the forskolin labeling sites to both halves of P-glycoprotein: similarity of the sites labeled by forskolin and prazosin. Mol Pharmacol 1994, 46, 329-337.
31. Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 1981, 41, 1967-1972.
32. Naito M, Tsuruo T. Competitive inhibition by verapamil of ATP-dependent high affinity vincristine binding to the plasma membrane of multidrug-resistant K562 cells without calcium ion involvement. Cancer Res 1989, 49, 1452-1455.
33. Safa AR, Glover CJ, Sewell JL, Meyers MB, Bielder JL, Felsted RL. Identification of the multidrug resistance-related membrane glycoprotein as an acceptor for calcium channel blocks. J Biol Chem 1987, 262, 7884-7888.
34. Safa AR. Photoaffinity labeling of the multidrug-resistance-related P-glycoprotein with photoactive analogs of verapamil. Proc Natl Acad Sci USA 1988, 85, 7187-7191.
35. Safa AR. Inhibition of azidopine binding to the multidrug resistance related gp 150-180 (P-glycoprotein) by modulators of multidrug resistance. Proc Am Assoc Cancer Res 1988, 29, 1160.
36. Yang CH, Mellado W, Horwitz SB. Azidopine photoaffinity labeling of multidrug resistance-associated glycoproteins. Biochem Pharmacol 1988, 37, 1417-1421.
37. Ford JM, Bruggeman E, Pastan I, Gottesman MM, Hait WN. Cellular and biochemical characterization of thioxanthenes for reversal of multidrug resistance in human and murine cell lines. Cancer Res 1990, 50, 1748-1756.
38. 939/941. Biochemistry 1994, 33, 5041-5048.
39. Cardarelli CO, Aksentijevich I, Pastan I, Gottesman MM. Differential effects of P-glycoprotein inhibitors on NIH3T3 cells transfected with wild-type (G185) or mutant (V185) multidrug transporters. Cancer Res 1995, 55, 1086-1091.
40. Bruggemann EP, Currier SJ, Gottesman MM, Pastan I. Characterization of the azidopine and vinblastine binding site of P-glycoprotein. J Biol Chem 1992, 267, 21020-21026.
41. Yusa K, Tsuruo T. Reversal mechanism of multidrug resistance by verapamil: direct binding of verapamil to P-glycoprotein on specific sites and transport of verapamil outward across the plasma membrane of K562/ADM cells. Cancer Res 1989, 49, 5002-5006.
42. Tamai I, Safa A. Azidopine noncompetitively interacts with vinblastine and cyclosporin A binding to P-glycoprotein in multidrug resistant cells. J Biol Chem 1991, 266, 16796-16800.
43. Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y. Increased accumulation of vincristine and adriamycin in drug-resistant P388 tumor cells following incubation with calcium antagonists and calmodulin inhibitors. Cancer Res 1982, 42, 4730-4733.
44. Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y. Potentiation of vincristine and adriamycin in human hematopoietic tumor cell lines by calcium antagonists and calmodulin inhibitors. Cancer Res 1983, 43, 2267-2272.
45. Akiyama S, Cornwell MM, Kuwano M, Pastan I, Gottesman MM. Most drugs that reverse multidrug resistance inhibit photoaffinity labelling of P-glycoprotein by a vinblastine analog. Mol Pharmacol 1988, 33, 144-147.
46. Ozols RF, Cunnion RE, Klecker RW, et al. Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients. J Clin Oncol 1987, 5, 641-647.
47. Kessel D, Wilberding C. Promotion of daunorubicin uptake and toxicity by the calcium antagonist tiapamil and its analogs. Cancer Treat Rep 1985, 69, 673-676.
48. Plumb JA, Wishart GC, Setanoians A, et al. Identification of a multidrug resistance modulator with clinical potential by analysis of synergistic activity in vitro, toxicity in vivo and growth delay in a solid human tumor xenograft. Biochem Pharmacol 1994, 47, 257-266.
49. Pereira E, Teodori E, Dei S, Gualtieri F, Guarnier-Suillerot A. Reversal of multidrug resistance by verapamil analogues. Biochem Pharmacol 1995, 50, 451-457.
50. Toffoli G, Simone F, Corona G, et al. Structure-activity relationship of verapamil analogs and reversal of multidrug resistance. Biochem Pharmacol 1995, 50, 1245-1255.
51. Eliason JF, Ramuz H, Yoshikubo T, Ishikawa T, Yamamoto T, Tsuruo T. Novel dithiane analogues of tiapamil with high activity to overcome multidrug resistance in vitro. Biochem Pharmacol 1995, 50, 187-196.
52. Tsuruo T, Iida H, Nojiri M, Tsukagoshi S, Sakurai Y. Circumvention of vincristine and adriamycin resistance in vitro and in vivo by calcium influx blockers. Cancer Res 1983, 43, 2905-2910.
53. Ramu A, Spanier R, Rahamimoff H, Fuks Z. Restoration of doxorubicin responsiveness in doxorubicin-resistant P388 murine leukaemia cells. Br J Cancer 1984, 50, 501-507.
54. Tsuruo T, Kawabata H, Nagumo N, et al. Potentiation of antitumor agents by calcium channel blockers with special reference to cross-resistance patterns. Cancer Chemother Pharmacol 1985, 15, 16-19.
55. Niwa K, Yamada K, Furukawa T, et al. Effect of a dihydropyridine analogue, 2-[benzyl(phenyl)amino] ethyl-1,4-dihydro-2,6-dimethyl-5-(5,5-dimethyl-2-oxo-1,3,2-dioxaphosphorinan-2- yl)-1-(2-morpholino-ethyl)-4-(3-nitrophenyl)-3-pyridinecarboxylate on reversing in vivo resistance of tumor cells to adriamycin. Cancer Res 1992, 52, 3655-3660.
56. Weir MR, Peppler R, Gomolka D, Handwerger BS. Evidence that the antiproliferative effect of verapamil on afferent and efferent immune responses is independent of calcium channel inhibition. Transplantation 1992, 54, 681-685.
57. Gruber A, Peterson C, Reizenstein P. D-verapamil and L-verapamil are equally effective in increasing vincristine accumulation in leukemic cells in vitro. Int J Cancer 1988, 41, 224-226.
58. Plumb JA, Milroy R, Kaye SB. The activity of verapamil as a resistance modifier in vitro in drug resistant human tumor cell lines is not stereospecific. Biochem Pharmacol 1990, 39, 787-792.
59. Hollt V, Kouba M, Dietel M, Vogt G. Stereoisomers of calcium antagonists which differ markedly in their potencies as calcium blockers are equally effective in modulating drug transport by P-glycoprotein. Biochem Pharmacol 1992, 43, 2601-2608.
60. Boer R, Haas S, Schodl A. Influence of dexniguldipine-HCl on rhodamine-123 accumulation in a multidrug-resistant leukaemia cell line: comparison with other chemosensitisers. Eur J Cancer 1994, 30A, 1117-1123.
61. Berg SL, Tolcher A, O'Shaughnessy JA, et al. Effect of R-verapamil on the pharmacokinetics of paclitaxel in women with breast cancer. J Clin Oncol 1995, 13, 2039-2042.
62. Motzer RJ, Lyn P, Fischer P, et al. Phase I/II trial of dexverapamil plus vinblastine for patients with advanced renal cell carcinoma. J Clin Oncol 1995, 13, 1958-1965.
63. Wilson WH, Jamis-Dow C, Bryant G, et al. Phase I and pharmacokinetic study of the multidrug resistance modulator dexverapamil with EPOCH chemotherapy. J Clin Oncol 1995, 13, 1985-1994.
64. Wilson WH, Bates SE, Fojo A, et al. Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy. J Clin Oncol 1995, 13, 1995-2004.
65. Ganapathi R, Grabowski D, Rouse W, Riegler F. Differential effect of the calmodulin inhibitor trifluoperazine on cellular accumulation, retention and cytotoxicty of anthracyclines in doxorubicin (adriamycin)-resistant P388 mouse leukemia cells. Cancer Res 1984, 44, 5056-5061.
66. Ganapathi R, Grabowski D, Schmidt H. Factors governing the modulation of vinca-alkaloid resistance in doxorubicin-resistant cells by the calmodulin inhibitor trifluoperazine. Biochem Pharmacol 1986, 35, 673-678.
67. Ford JM, Prozialeck WC, Hait WN. Structural features determining activity of phenothiazines and related drugs for inhibition of cell growth and reversal of multidrug resistance. Mol Pharmacol 1989, 35, 105-115.
68. Johnstone EC, Crow TJ, Frith CD, Carney MWD, Price JS. Mechanism of the antipsychotic effect in the treatment of acute schizophrenia. Lancet 1978, 1, 848-851.
69. Post ML, Kennard U, Horn AS. Stereoselective blockade of the dopamine receptor and the X-ray structures of alpha and beta-flupenthixol. Nature 1975, 256, 342-343.
70. Huff RM, Molinoff B. Assay of dopamine receptors with [α-3H] flupenthixol. J Pharmacol Exp Ther 1984, 232, 57-61.
71. Nielsen IM, Pedersen V, Nymark M, et al. Comparative pharmacology of flupenthixol and some reference neuroleptics. Acta Pharmacol Toxicol 1973, 33, 353-362.
72. Twentyman PR, Fox NE, White DJG. Cyclosporin A and its analogues as modifiers of adriamycin and vincristine resistance in a multi-drug resistant human lung cancer cell line. Br J Cancer 1987, 56, 55-57.
73. Hait WN, Stein JM, Koletsky AJ, Harding MW, Handschumacher RE. Activity of cyclosporin A and a non-immunosuppressive cyclosporin on multidrug resistant leukemic cell lines. Cancer Commun 1989, 1, 35-43.
74. Silbermann MH, Boersma AWM, Jansen ALW, Scheper RJ, Herweijer H, Nooter K. Effects of cyclosporin A and verapamil on the intracellular daunorubicin accumulation in Chinese hamster ovary cells with increasing levels of drug-resistance. Int J Cancer 1989, 44, 722-726.
75. Slater LM, Sweet P, Stupecky M, Wetzel MW, Gupta S. Cyclosporin A corrects daunorubicin resistance in Ehrlich ascites carcinoma. Br J Cancer 1986, 54, 235-238.
76. Osieka R, Seeber S, Pannenbacker R, Soll D, Glatte P, Schmidt CG. Enhancement of etoposide-induced cytotoxicity by cyclosporin A. Cancer Chemother Pharmacol 1986, 18, 198-202.
77. Chambers SK, Hait WN, Kacinski BM, Keyes SR, Handschumacher RE. Enhancement of anthracycline growth inhibition in parent and multidrug-resistant Chinese hamster ovary cells by cyclosporin A and its analogues. Cancer Res 1989, 46, 6275-6279.
78. Gaveriaux C, Boesch D, Boilsterli JJ, et al. Overcoming multidrug resistance in Chinese hamster ovary cells in vitro by cyclosporin A (Sandimmune) and non-immunosuppressive derivatives. Br J Cancer 1989, 60, 867-871.
79. Slater L, Sweet P, Wetzel M, Stupecky M, Osann K. Comparison of cyclosporin A, verapamil, PSC-833 and cremophor EL as enhancing agents of VP-16 in murine lymphoid leukemias. Leuk Res 1995, 19, 543-548.
80. Boesch D, Muller K, Pourtier-Manzanedo A, Loor F. Restoration of daunomycin retention in multidrug-resistant P388 cells by submicromolar concentrations of SDZ PSC 833, a nonimmunosuppressive cyclosporin derivative. Exp Cell Res 1991, 196, 26-32.
81. Jachez B, Nordmann R, Loor F. Restoration of taxol sensitivity of multidrug-resistant cells by the cyclosporine SDZ PSC 833 and the cyclopeptolide SDZ 280-446. J Natl Cancer Inst 1993, 85, 478-483.
82. Jiang XR, Kelsey SM, Wu YL, Newland AC. Circumvention of P-glycoprotein-mediated drug resistance in human leukaemic cells by non-immunosuppressive cyclosporin D analogue, SDZ PSC 833. Br J Haematol 1995, 90, 375-383.
83. Fisher GA, Sikic BI. Clinical studies with modulators of multidrug resistance. Hematol Oncol Clin North Am 1995, 9, 363-382.
84. Loor F, Boesch D, Gaveriaux C, Jachez B, Dourtier-Manzanedo A, Emmer G. SDZ 280-446, a novel semisynthetic cyclopeptide: in vitro and in vivo circumvention of P-glycoprotein-mediated tumor cell multidrug resistance. Br J Cancer 1992, 65, 11-18.
85. Arceci RJ, Croop JM, Horwitz SB, Housman D. The gene encoding multidrug resistance is induced and expressed at high levels during pregnancy in the secretory epithelium of the uterus. Proc Natl Acad Sci USA 1988, 85, 4350-4354.
86. Yang C-PH, DePinho SH, Greenberger LM, Arceci RJ, Horwitz SB. Progesterone interacts with P-glycoprotein in multidrug-resistant cells and in the endometrium of gravid uterus. J Biol Chem 1989, 264, 782-788.
87. Yang C-PH, Cohen D, Greenberger LM, Hsu SH, Horwitz SB. Differential transport properties of two mdr gene products are distinguished by progesterone. J Biol Chem 1990, 265, 10282-10288.
88. Fleming GF, Amato JM, Agresti M, Safa AR. Megestrol acetate reverses multidrug resistance and interacts with P-glycoprotein. Cancer Chemother Pharmacol 1992, 29, 445-449.
89. Aisner J, Tchekmedyian NS, Tait N, Parnes H, Novak M. Studies of high-dose megestrol acetate: potential applications in cachexia. Semin Oncol 1988, 15S, 68-75.
90. Ramu A, Glaubiger D, Fuks Z. Reversal of acquired resistance to doxorubicin in P388 murine leukemia cells by tamoxifen and other triparanol analogues. Cancer Res 1984, 44, 4392-4395.
91. Foster BJ, Grotzinger KR, McKoy WM, Rubinstein LV, Hamilton TC. Modulation of induced resistance to adriamycin in two human breast cancer cell lines with tamoxifen or perhexiline maleate. Cancer Chemother Pharmacol 1988, 22, 147-152.
92. DeGregorio MW, Ford JM, Benz CC, Wiebe VJ. Toremifene: pharmacologic and pharmacokinetic basis of reversing multidrug resistance. J Clin Oncol 1989, 7, 1359-1364.
93. r, by toremifene and its modulation by alpha 1 acid glycoprotein. Eur J Cancer 1990, 26, 432-436.
94. Kirk J, Houlbrook S, Stuart NSA, Stratford IJ, Harris AL, Carmichael J. Differential modulation of doxorubicin toxicity to multidrug and intrinsically drug resistant cell lines by antioestrogens and their major metabolites. Br J Cancer 1993, 67, 1189-1195.
95. r 170,000 glycoprotein binding studies. Cancer Res 1994, 54, 441-447.
96. Desai PB, Bhardwaj R, Damle B. Effect of tamoxifen on mitoxantrone cytotoxicity in drug-sensitive and multidrug-resistant MCF-7 cells. Cancer Chemother Pharmacol 1995, 36, 368-372.
97. Callaghan R, Higgins CF. Interaction of tamoxifen with the multidrug resistance P-glycoprotein. Br J Cancer 1995, 71, 294-299.
98. Jordan VC, Bain RR, Brown RR, Gosden B, Santos MA. Determination and pharmacology of a new hydroxylated metabolite of tamoxifen observed in patient sera during therapy for advanced breast cancer. Cancer Res 1983, 43, 1446-1450.
99. Nelson JA, Drake S. Potentiation of methotrexate toxicity by dipyridamole. Cancer Res 1984, 44, 2493-2496.
100. Grem JL, Fischer PH. Augmentation of 5-flourouracil cytotoxicity in human colon cancer cells by dipyridamole. Cancer Res 1985, 45, 2967-2972.
101. Jekunen A, Vick J, Sanga R, Chan TCK, Howell SB. Synergism between dipyridamole and cisplatin in human ovarian carcinoma cells in vitro. Cancer Res 1992, 52, 3566-3571.
102. Howell SB, Hom D, Sanga R, Vick JS, Abramson IS. Comparison of the synergistic potentiation of etoposide, doxorubicin and vinblastine cytotoxicity by dipyridamole. Cancer Res 1989, 49, 3178-3183.
103. Howell SB, Hom DK, Sanga R, Vick JS, Chan TCK. Dipyridamole enhancement of etoposide sensitivity. Cancer Res 1989, 49, 4147-4153.
104. Chen HX, Bamberger U, Heckel A, Guo X, Cheng YC. BIBW 22, a dipyridamole analogue, acts as a bifunctional modulator on tumor cells by influencing both P-glycoprotein and nucleoside transport. Cancer Res 1993, 53, 1974-1977.
105. Chauffert B, Martin M, Hammann A, Michel MF, Martin F. Amiodarone-induced enhancement of doxorubicin and 4′-deoxydoxorubicin cytotoxicity to rat colon cancer cells in vitro and in vivo. Cancer Res 1986, 46, 825-830.
106. Tsuruo T, Iida H, Kitatani Y, Yokota K, Tsukagoshi S, Yakurai Y. Effects of quinidine and related compounds on cytotoxicity and cellular accumulation of vincristine and adriamycin in drug-resistant tumor cells. Cancer Res 1984, 44, 4303-4307.
107. Zamora JM, Pearce HL, Beck WT. Physical-chemical properties shared by compounds that modulate multidrug resistance in human leukemic cells. Mol Pharmacol 1988, 33, 454-462.
108. Beck WT, Cirtain MC, Glover CJ, Felsted RL, Safa AR. Effects of indole alkaloids on multidrug resistance and labeling of P-glycoprotein by a photoaffinity analog of vinblastine. Biochem Biophys Res Commun 1988, 153, 959-966.
109. Pearce HL, Safa AR, Bach NJ, Winter MA, Cirtain MC, Beck WT. Essential features of the P-glycoprotein pharmacophore as defined by a series of reserpine analogs that modulate multidrug resistance. Proc Natl Acad Sci USA 1989, 86, 5128-5132.
110. Hait WN, Gesmonde JF, Murren JR, Yang JM, Chen HX, Reiss M. Terfenadine (Seldane): a new drug for restoring sensitivity to multidrug resistant cancer cells. Biochem Pharmacol 1993, 45, 401-406.
111. Hu YP, Robert J. Azelastine and flezelastine as reversing agents of multidrug resistance: pharmacological and molecular studies. Biochem Pharmacol 1995, 50, 169-175.
112. Hyafil F, Vergely C, Du Vignaud P, Grand-Perret T. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res 1993, 53, 4595-4602.
113. Pierre A, Dunn TA, Kraus-Berthier L, et al. In vitro and in vivo circumvention of multidrug resistance by Servier 9788, a novel triazinoaminopiperidine derivative. Invest New Drugs 1992, 10, 137-148.
114. Soudon J, Berlion M, Lucas C, Haddad P, Bizzari JP, Calvo F. In vitro activity of S 9788 on a multidrug-resistant leukemic cell line and on normal hematopoietic cells - reversal of multidrug resistance by sera from phase I-treated patients. Cancer Chemother Pharmacol 1995, 36, 195-203.
115. Merlin JL, Guerci A, Marchai S, et al. Comparative evaluation of S9788, verapamil and cyclosporine A in K562 human leukemia cell lines and in P-glycoprotein-expressing samples from patients with hematologic malignancies. Blood 1994, 84, 262-269.
116. Smith CD, Carmeli S, Moore RE, Patterson GML. Scytophycins, novel microfilament-depolymerizing agents which circumvent P-glycoprotein-mediated multidrug resistance. Cancer Res 1993, 53, 1343-1347.
117. Smith CD, Zhang X, Mooberry SL, Patterson GML, Moore RE. Cryptophycin: a new antimicrotubule agent active against drug-resistant cells. Cancer Res 1994, 54, 3779-3784.
118. Smith CD, Prinsep MR, Caplan FR, Moore RE, Patterson GM. Reversal of multiple drug resistance by tolyporphin, a novel cyanobacterial natural product. Oncol Res 1994, 6, 211-218.
119. Hu XF, Martin TJ, Bell DR, Luise M, Zalcberg JR. Combined use of cyclosporin A and verapamil in modulating multidrug resistance in human leukemia cell lines. Cancer Res 1990, 50, 2953-2957.
120. Osann K, Sweet P, Slater LM. Synergistic interaction of cyclosporin A and verapamil on vincristine and daunorubicin resistance in multidrug-resistant human leukemia cells in vitro. Cancer Chemother Pharmacol 1992, 30, 152-154.
121. Ramu A, Ramu N. Reversal of multidrug resistance by phenothiazines and structurally related compounds. Cancer Chemother Pharmacol 1992, 30, 165-173.
122. Ramu A, Ramu N. Reversal of multidrug resistance by bis(phenylalkyl)amines and structurally related compounds. Cancer Chemother Pharmacol 1994, 34, 423-430.
123. Dodic N, Dumaitre B, Daugan A, Pianetti P. Synthesis and activity against multidrug resistance in Chinese hamster cells of new acridone-4-carboxamides. J Med Chem 1995, 38, 2418-2426.
124. Chiba P, Burghofer S, Richter E, Tell B, Moser A, Ecker G. Synthesis, pharmacologic activity, and structure-activity relationships of a series of propafenone-related modulators of multidrug resistance. J Med Chem 1995, 38, 2789-2793.
125. Carlsen SA, Till JE, Ling V. Modulation of drug permeability in Chinese hamster ovary cells - possible role for phosphorylation of surface glycoproteins. Biochim Biophys Acta 1977, 467, 238-250.
126. Center MS. Evidence that adriamycin resistance in Chinese hamster lung cells is regulated by phosphorylation of a plasma membrane glycoprotein. Biochem Biophys Res Commun 1983, 115, 159-166.
127. r 170,000 to 180,000 glycoprotein specific to multidrug-resistant tumor cells: effects of verapamil, trifluoperazine, and phorbol esters. Cancer Res 1987, 47, 2860-2865.
128. Fine RL, Patel Ja, Chabner BA. Phorbol esters induce multidrug resistance in human breast cancer cells. Proc Natl Acad Sci USA 1988, 85, 582-586.
129. Ma L, Marquardt D, Takemoto L, Center MS. Analysis of P-glycoprotein phosphorylation in HL-60 cells isolated for resistance to vincristine. J Biol Chem 1991, 266, 5593-5599.
130. Meyers MB. Protein phosphorylation in multidrug resistant Chinese hamster cells. Cancer Commun 1989, 1, 233-241.
131. Mellado W, Horwitz SB. Phosphorylation of the multidrug resistance associated glycoprotein. Biochemistry 1987, 26, 6900-6904.
132. Center MC. Mechanisms regulating cell resistance to adriamcyin - evidence that drug accumulation in resistant cells is modulated by phosphorylation of a plasma membrane glycoprotein. Biochem Pharmacol 1985, 34, 1471-1476.
133. Kemp BE, Pearson RB. Protein kinase recognition sequence motifs. Trends Biochem Sci 1990, 15, 342-346.
134. Kennelly PJ, Krebs EG. Consensus sequences as substrate specificity determinants for protein kinases and protein phosphatases. J Biol Chem 1991, 266, 15555-15558.
135. Chambers TC, McAvoy EM, Jacobs JW, Eilon G. Protein kinase C phosphorylates P-glycoprotein in multidrug resistant human KB carcinoma cells. J Biol Chem 1990, 265, 7679-7686.
136. Aftab DT, Hait WN. Effects of phorbol 12-myristate 13-acetate on drug accumulation and P-glycoprotein phosphorylation in sensitive and multidrug resistant MCF-7 cells. Proc Am Assoc Cancer Res 1992, 33, 2821.
137. Aftab DT, Yang JM, Hait WN. Functional role of phosphorylation of the multidrug transporter (P-glycoprotein) by protein kinase C in multidrug-resistant MCF-7 cells. Oncol Res 1994, 6, 59-70.
138. Chambers TC, Chalikonda I, Eilon G. Correlation of protein kinase C translocation, P-glycoprotein phosphorylation and reduced drug accumulation in multidrug resistant human KB cells. Biochem Biophys Res Commun 1990, 169, 253-259.
139. Ido M, Asao T, Sakurai M, Inagaki M, Saito M, Hidaka H. An inhibitor of protein kinase C, 1-(5-isoquinolinylsulfonyl)-2-methylpiperazine (H-7) inhibits TPA-induced reduction of vincristine uptake from P388 murine leukemic cell. Leuk Res 1986, 10, 1063-1069.
140. Ferguson PF, Chen Y. Transient protection of cultured human cells against antitumor agents by 12-O-tetradecanoylphorbol-13-acetate. Cancer Res 1987, 47, 433-441.
141. Gollapudi S, Patel K, Jain V, Gupta S. Protein kinase C isoforms in multidrug resistant P388/ADR cells: a possible role in daunorubicin transport. Cancer Lett 1992, 62, 69-75.
142. Blobe GC, Sachs CW, Khan WA, et al. Selective regulation of expression of protein kinase C isoenzymes in multidrug-resistant MCF-7 cells: functional significance of enhanced expression of PKCα. J Biol Chem 1993, 268, 658-664.
143. Dong Z, Ward NE, Fan D, Gupta KP, O'Brian CA. In vitro model for intrinsic drug resistance: effects of protein kinase C activators on the chemosensitivity of cultured human colon cancer cells. Mol Pharmacol 1991, 39, 563-569.
144. O'Brian CA, Fan C, Ward NE, et al. Transient enhancement of multidrug resistance by the bile acid deoxycholate in murine fibrosarcoma cells in vitro. Biochem Pharmacol 1991, 41, 797-806.
145. Mori T, Takai Y, Minakuchi R, Yu B, Nishizuka Y. Inhibitory action of chlorpromazine, dibucaine and other phospholipid-interacting drugs on calcium-activated, phospholipid-dependent protein kinase. J Biol Chem 1980, 255, 8378-8380.
146. Schatzman RC, Wise BC, Kuo JF. Phospholipid-sensitive calcium-dependent protein kinase: inhibition by anti-psychotic drugs. Biochem Biophys Res Commun 1981, 98, 669-676.
147. O'Brian CA, Liskamp RM, Solomon DH, Weinstein IB. Inhibition of protein kinase C by tamoxifen. Cancer Res 1985, 45, 2462-2465.
148. Walker RJ, Lazzaro VA, Duggin GG, Horvath JS, Tiller DJ. Cyclosporin A inhibits protein kinase C activity: a contributing mechanism in the development of nephrotoxicity? Biochem Biophys Res Commun 1989, 160, 409-415.
149. Aftab DT, Ballas LM, Loomis CR, Hait WN. Structure - activity relationships of phenothiazines and related drugs for inhibition of protein kinase C. Mol Pharmacol 1991, 40, 798-805.
150. Foxwell BMJ, Mackie A, Ling V, Ryffel B. Identification of the multidrug resistance-related P-glycoprotein as a cyclosporin binding protein. Mol Pharmacol 1989, 36, 543-546.
151. Posada JA, McKeegan EM, Worthington KF, Morin MJ, Jaken S, Tritton TR. Human multidrug resistant KB cells overexpress protein kinase C: involvement in drug resistance. Cancer Commun 1989, 1, 285-292.
152. Galski H, Sullivan M, Willingham MC, et al. Expression of a human multidrug resistance cDNA (MDR-1) in the bone marrow of transgenic mice: resistance to daunomycin induced leukopenia. Mol Cell Biol 1989, 9, 4357-4363.
153. Smith CD, Zilfou JT. Circumvention of P-glycoprotein-mediated multiple drug resistance by phosphorylation modulators is independent of protein kinases. J Biol Chem 1995, 270, 28145-28152.
154. Jaffrezou JP, Herbert JM, Levade T, Gau MN, Chatelain P, Laurent G. Reversal of multidrug resistance by calcium channel blocker SR33557 without photoaffinity labeling of P-glycoprotein. J Biol Chem 1991, 266, 19858-19864.
155. Sachs CW, Safa AR, Harrison SD, Fine RL. Partial inhibition of multidrug resistance by safingol is independent of modulation of P-glycoprotein substrate activities and correlated with inhibition of protein kinase C. J Biol Chem 1995, 270, 26639-26648.
156. ++ after heat shock. Biochem Biophys Res Commun 1986, 137, 826-833.
157. Calderwood SK, Stevenson MA. Inducers of the heat shock response stimulate phospholipase C and phospholipase A2 activity in mammalian cells. J Cell Physiol 1993, 155, 248-256.
158. Yang JM, Chin KV, Hait WN. Involvement of phospholipase C in heat-shock-induced phosphorylation of P-glycoprotein in multidrug resistant human breast cancer cells. Biochem Biophys Res Commun 1995, 210, 21-30.
159. Ichikawa M, Yoshimura A, Furukawa T, Sumizawa T, Nakazima Y, Akiyama S. Glycosylation of P-glycoprotein in a multidrug-resistant KB cell line, and in the human tissues. Biochem Biophys Acta 1991, 1073, 309-315.
160. Beck WT, Cirtain MC. Continued expression of Vinca alkaloid resistance by CCRF-CEM cells after treatment with tunicamycin or pronase. Cancer Res 1982, 42, 184-189.
161. Kramer R, Weber TK, Arceci R, et al. Inhibition of N-linked glycosylation of P-glycoprotein by tunicamycin results in a reduced multidrug resistance phenotype. Br J Cancer 1995, 71, 670-675.